Open access
Aug 2026
The benefit of LDL-C levels below 55 mg/dL in ESKD patients under statin treatment: A target trial emulation study.
BACKGROUND AND AIMS Achieving optimal low-density lipoprotein cholesterol (LDL-C) levels through statin therapy is a cornerstone of cardiovascular disease (CVD) prevention. However, its benefit in end-stage kidney disease (ESKD) remains uncertain, largely because two major randomized controlled trials-4D Study and AURO...
C. Yen, Pei-Chun Fan, Jia-Jin Chen et al.
· Atherosclerosis · 0 citations